<div id="readability-page-1"><p>High‑risk, high‑reward stocks appeal to investors who can handle sharp swings in price. These companies are still early in their growth journeys, but if their key catalysts play out, the returns can be explosive. According to analysts, three names worth considering now are Kura Oncology (KURA), Angel Studios (ANGX), and Immuneering (IMRX).</p><h3>Claim 30% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>These stocks were identified using the TipRanks Stock Screener tool. All three stocks have a Strong Buy consensus rating from analysts and an upside potential of over 200% in the next 12 months.</p> <h2><strong>1. Kura Oncology (KURA)</strong></h2> <p>Kura Oncology is developing targeted cancer drugs for patients with specific genetic profiles. The company's lead programs focus on blocking cancer‑driving pathways found in aggressive tumors. Early data have been encouraging, and analysts think upcoming clinical results could be major catalysts for the stock.</p> <p>The upside is meaningful, but risks remain. Drug development is unpredictable, and setbacks in trials or regulatory delays could hit the stock hard. Still, if Kura delivers strong data, analysts believe the shares could move sharply higher.</p> <p>Turning to Wall Street, KURA stock has a Strong Buy consensus rating based on nine Buys and one Hold assigned in the last three months. At $28.13, the average Kura Oncology stock price target implies upside potential of 218.57%.</p></div>

IMRX

SBIO

LABU

IBBQ

<p>Analysts recommend three high-risk, high-reward stocks: Kura Oncology (KURA), Angel Studios (ANGX), and Immuneering (IMRX), all with a Strong Buy consensus and over 200% upside potential in the next year. Kura Oncology focuses on targeted cancer drugs, showing promising early data. Despite the inherent risks in drug development, analysts predict significant stock movement if clinical results are favorable, with a price target of $28.13 indicating a 218.57% upside.</p>

Tip Ranks

Immuneering

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

Kura Oncology

Angel Studios

3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026